Reliq Health Technologies Inc.

SADIF Investment Analytics (5/25/23) "RHT has a bright prospect, fair financials and good earnings quality."

SADIF Investment Analytics (4/3/23) "RHT's stock has been upgraded to Above Average from Average."

Jefferson Research (1/20/23) "RHT's balance sheet rating improved during Q1/23."

Jefferson Research (12/15/22) "The valuation for RHT suggests a lower amount of price risk."

Clive Maund, CliveMaund.com (11/22/22) "This is a good point to add to positions or make new purchases of RHQ."

Dr. Douglas Loe, Leede Jones Gable (11/4/22) "RHT added 50 new nursing home clients in Florida to its network."

Clive Maund, CliveMaund.com (11/1/22) "The dip of recent days presents us with a better entry point for RHT."

Awakn Life Sciences Corp.

Clive Maund, CliveMaund.com (9/11/22) "AWKNF's exceptionally positive technical setup keeps getting better."

Clive Maund, CliveMaund.com (9/5/22) "AWKNF is a stock that it is thought to be worth going overweight on."

Clive Maund, CliveMaund.com (8/16/22) "AWKN is now in position to break out into a new bull market."

Andrew Partheniou, Stifel (8/15/22) "AWKN announced its first KARE licensing agreement."

Reliq Health Technologies Inc.

Jefferson Research (7/14/22) "RHT's quality of net income earnings is extremely high."

Jefferson Research (6/10/22) "RHT is showing strong earnings quality and cash flow quality."

Clive Maund, CliveMaund.com (4/26/22) "RHT is rated an Immediate Buy here."

Clive Maund, CliveMaund.com (8/29/21) "RTG's vigorous uptrend is probably targeting the CA$1.30–1.40 area."

Clive Maund, CliveMaund.com (1/8/21) "The slight drop today [of RHT shares] on very low volume is interpreted as a sign that it is ready to turn higher again now or very soon, and it is therefore rated an immediate buy."

Leonovus Inc.

Clive Maund, CliveMaund.com (7/17/20) "LTV could do a moonshot from its current very low price."

Nobilis Health Corp.

Northern Capital, Seeking Alpha (8/4/16) "$HLTH turning a profit this year is significant; we could see higher earnings in the future."

Russell Stanley, Research Capital Corporation (8/4/16) "We view HLTH's results as demonstrating solid sequential improvement in terms of margins, receivables collection and financial reporting timeliness."

Sheila Broughton, PI Financial (8/3/16) "We expect HLTH's management to complete further accretive acquisitions."

Russell Stanley, Research Capital Corporation (8/3/16) "HLTH's [Q2/16] results demonstrated sequential revenue and EBITDA improvement from Q1/16 levels, reflecting seasonality in the business."

Jennifer Poland, BioTuesdays (8/3/16) "HLTH reported revenue of $61.9-million for the second quarter, an increase of 27% from a year ago."

Russell Stanley, Research Capital Corporation (8/2/16) "We like HLTH's acquisition of Arizona Vein & Vascular Center, as it expands the company's presence in Arizona and augments the service breadth."

Neil Maruoka, Canaccord Genuity (8/2/16) "HLTH has indicated that it continues to pursue additional accretive acquisitions."

Neil Maruoka, Canaccord Genuity (7/13/16) "We are initiating coverage of HLTH with a Buy rating;we see upside to our valuation with further Athas-generated organic growth, and future accretive acquisitions of surgical facilities."

Russell Stanley, Research Capital Corporation (7/11/16) "We view Mr. Ken Efird's appointment positively, as it represents a promotion-from-within HLTH for a very capable executive."

Charles Haff, Craig-Hallum Capital (6/20/16) "HLTH's organic business is performing better than our previous expectations."

Russell Stanley, Research Capital Corporation (5/25/16) "HLTH is an undervalued play on growing demand for high acuity surgery in the U.S."

Sheila Broughton, PI Financial (5/13/16) "HLTH continues to focus on higher acuity cases to increase both revenue per case and overall operating margin."

Dana Hambly, Stephens Inc. (5/12/16) "HLTH's revenue growth continues to impress rising 35.5%."

Russell Stanley, Research Capital Corporation (5/3/16) "HLTH is an undervalued play on growing demand for high acuity surgery; it's a Buy."

Inovio Pharmaceuticals Inc.

Jason McCarthy, Maxim Group (5/2/16) "INO completed its acquisition of Needle-Free Technology, which could be a paradigm shifting technology."

Nobilis Health Corp.

Shane Matte, BioTuesdays (5/2/16) "HLTH launched Concertis, a comprehensive technology platform that will develop new payment and delivery methodologies to enhance value for patients, payers, and providers."

Darspal S. Mann, Seeking Alpha (4/22/16) "The risk/reward ratio is favorable enough to monitor HLTH closely."

Shane Matte, BioTuesdays (4/7/16) "HLTH will now have both in-network and out-of-network revenues in the Dallas-Fort Worth market."

Sheila Broughton, PI Financial (3/31/16) "HLTH's 2015 results were at the very top end of guidance."

Reliq Health Technologies Inc.

Nick Hodge, Outsider Club (3/28/16) "MSD is pursuing a roll-up strategy whereby it will grow through acquisitions that could lead it to several million in revenue in fairly short order."

Nobilis Health Corp.

Russell Stanley, Research Capital Corporation (3/28/16) "HLTH is an undervalued, overlooked play on growing demand for high acuity surgical procedures."

James West, Midas Letter (3/18/16) "HLTH delivered stellar Q4/15 and year-end results."

Russell Stanley, Research Capital Corporation (3/17/16) "HLTH's change to now consider 'distressed asset' deals is positive."

Sheila Broughton, PI Financial (3/17/16) "HLTH's 2015 revenue increased 173% to $229M, for an 18.4% margin."

Russell Stanley, Research Capital Corporation (3/16/16) "HLTH reported Q4 results that beat our estimates for revenue."

Russell Stanley, Research Capital Corporation (3/11/16) "HLTH's timely Q4/15 reporting should further derisk the stock."

The Life Sciences Report Interview with Bruce Campbell (2/3/16) "HLTH is now getting to levels we think are very attractive."

Russell Stanley, Research Capital Corporation (2/2/16) "Recently, HLTH's CEO acquired 31.7K shares, and other insiders, 21K."

Sheila Broughton, PI Financial (1/20/16) "HLTH's Q4/15 revenue increased 105–130% over Q4/14."

Russell Stanley, Research Capital Corporation (1/20/16) "HLTH's reiteration of FY16 guidance is a strong positive."

Russell Stanley, Research Capital Corporation (1/15/16) "HLTH currently trades at a discount that is unreasonably high."

Russell Stanley, Research Capital Corporation (1/14/16) "HLTH is likely to announce an acquisition in Q1/16."

Russell Stanley, Research Capital Corporation (1/13/16) "HLTH's release of its financials should be a major lift to the stock."

Sheila Broughton, PI Financial (1/13/16) "At Q3/15E, HLTH's YTD revenue was 214% over the same period's in 2014."

Dana Hambly, Stephens Inc. (1/13/16) "We maintain our Overweight rating on NHC."

James West, Midas Letter (1/13/16) "NHC filed its Q3/15 financials, allaying fears of accounting problems."

Sheila Broughton, PI Financial (1/11/16) "HLTH's management reiterated its 2015 and 2016 guidance."

Russell Stanley, Research Capital Corporation (1/6/16) "HLTH management's breakdown of restatement items is a silver lining."

Reliq Health Technologies Inc.

GeoInvesting (12/29/15) "MSD continues to maximize the value of its assets through potential partnerships and/or acquisitions."